1. Introduction {#sec1-ijms-17-01800}
===============

Obesity is a risk factor for a variety of diseases \[[@B1-ijms-17-01800],[@B2-ijms-17-01800]\], including the development and progression of chronic kidney disease (CKD) \[[@B3-ijms-17-01800]\]. Obesity is linked to metabolic syndrome, which is characterized by an increase in visceral fat, insulin resistance, hyperinsulinemia and dyslipidemia. Metabolic syndrome contributes to the development of type 2 diabetes, hypertension, cardiovascular disease \[[@B4-ijms-17-01800]\] and CKD \[[@B5-ijms-17-01800]\]. Type 2 diabetes and hypertension are widely recognized as risk factors for CKD \[[@B6-ijms-17-01800]\]. There are many reports indicating that an increase in intrarenal angiotensinogen (AGT) and the activation of the renin-angiotensin system (RAS) are involved in CKD \[[@B7-ijms-17-01800],[@B8-ijms-17-01800],[@B9-ijms-17-01800],[@B10-ijms-17-01800],[@B11-ijms-17-01800]\]. The intrarenal RAS is activated in obesity \[[@B3-ijms-17-01800],[@B12-ijms-17-01800],[@B13-ijms-17-01800]\].

The angiotensin II receptor blocker (ARB) is reported to prevent the progress of renal injury in an experimental model for metabolic syndrome \[[@B14-ijms-17-01800]\]. However, in some cases, the progress of renal injury cannot be suppressed by ARB treatments \[[@B6-ijms-17-01800]\].

The Reduction of End points in Non-insulin-dependent diabetes with the Angiotensin II Antagonist Losartan (RENAAL) study \[[@B6-ijms-17-01800]\] reported that treatment with the ARB losartan (50--100 mg once daily) delayed time to the first cardiovascular event, decreased cardiovascular morbidity and mortality, reduced proteinuria and decreased the rate of the progression of renal disease in patients with type 2 diabetes and nephropathy. A total of 1513 patients were enrolled in this randomized, double-blind study comparing losartan with placebo, both taken in addition to conventional antihypertensive treatment for a mean of 3.4 years. However, non-responders still exist for ARB \[[@B2-ijms-17-01800]\].

The intrarenal RAS is regulated by multiple independent mechanisms \[[@B15-ijms-17-01800]\]. Others and we have previously reported that the urinary AGT excretion rate could be a marker of intrarenal RAS status in hypertension \[[@B9-ijms-17-01800],[@B16-ijms-17-01800],[@B17-ijms-17-01800],[@B18-ijms-17-01800]\], as well as in CKD \[[@B7-ijms-17-01800],[@B19-ijms-17-01800],[@B20-ijms-17-01800],[@B21-ijms-17-01800],[@B22-ijms-17-01800]\]. However, the effect of ARB on urinary AGT has not yet been examined in patients with metabolic syndrome. Therefore, this study was performed to examine the following two hypotheses: (1) an ARB could decrease urinary excretions of albumin and AGT in patients with metabolic syndrome; and (2) urinary AGT excretion could be a prognostic marker of the albuminuria reduction effects of ARB in patients with metabolic syndrome.

2. Results {#sec2-ijms-17-01800}
==========

2.1. Description of the Study Population {#sec2dot1-ijms-17-01800}
----------------------------------------

Initially, 33 patients were recruited. Afterwards, nine patients were excluded (six participants withdrew from the study, and three participants were excluded because of incomplete samplings), and consequently, 24 patients were analyzed ([Figure S1](#app1-ijms-17-01800){ref-type="app"}). Clinical characteristics and baseline laboratory data are summarized in [Table 1](#ijms-17-01800-t001){ref-type="table"} and [Table 2](#ijms-17-01800-t002){ref-type="table"}, respectively.

2.2. Administration of Olmesartan {#sec2dot2-ijms-17-01800}
---------------------------------

Olmesartan significantly decreased blood pressure (*p* \< 0.05; [Figure 1](#ijms-17-01800-f001){ref-type="fig"}), but did not affect the metabolic parameters. Body weight (kg), waist circumference (cm), fasting blood sugar (FBS) and triglyceride (TG) were unchanged after treatment with olmesartan. Plasma renin activity (PRA) was increased after treatment with olmesartan (*p* \< 0.05; [Figure 2](#ijms-17-01800-f002){ref-type="fig"}a). Olmesartan did not affect plasma aldosterone concentration ([Figure 2](#ijms-17-01800-f002){ref-type="fig"}b).

2.3. Albuminuria Reduction Effects of Olmesartan {#sec2dot3-ijms-17-01800}
------------------------------------------------

The average urinary albumin/creatinine (Cr) ratio (UAlbCR) (*p* \< 0.05; [Figure 3](#ijms-17-01800-f003){ref-type="fig"}) and the average urinary AGT/creatinine ratio (UAGTCR) (*p* \< 0.05; [Figure 4](#ijms-17-01800-f004){ref-type="fig"}) were decreased after the 24-week treatment with olmesartan. Patients were divided into two groups based on whether or not UAlbCR decreased less than 50% ([Figure 5](#ijms-17-01800-f005){ref-type="fig"}a). The data of the clinical characteristics of the good responder group and the poor responder group at the baseline are given in the [Table 3](#ijms-17-01800-t003){ref-type="table"}. Logistic analysis was conducted by UAGTCR before the treatments. When a receiver operating characteristic (ROC) curve was plotted, the area under the curve (AUC) was 0.694. When the cutoff value of UAGTCR before the treatments was set as 13.9 μg/g Cr, the maximum Youden index (0.500; [Figure 5](#ijms-17-01800-f005){ref-type="fig"}b,c; specificity: 11/12 = 91.7% and sensitivity: 07/12 = 58.3%) was obtained.

Based on this cutoff value of UAGTCR at baseline, all patients were divided into two groups: the higher (Group H, *N* = 16) and the lower (Group L) group. Clinical characteristics ([Table 4](#ijms-17-01800-t004){ref-type="table"}) and baseline laboratory data ([Table 5](#ijms-17-01800-t005){ref-type="table"}) were not significantly different between Group H and Group L. Under these circumstances, ΔUAlbCR was significantly lower in Group H than in Group L ([Figure 6](#ijms-17-01800-f006){ref-type="fig"}a). Moreover, the % change in UAlbCR was significantly lower in Group H than in Group L ([Figure 6](#ijms-17-01800-f006){ref-type="fig"}b).

3. Discussion {#sec3-ijms-17-01800}
=============

This study was performed to demonstrate that an ARB could exert albuminuria reduction effects in patients with metabolic syndrome and that urinary AGT excretion could be a prognostic marker of the albuminuria reduction effects of ARB in patients with metabolic syndrome. Macroalbuminuria is a better risk marker than the estimated glomerular filtration rate (eGFR) in population screening of individuals who are at risk for accelerated GFR loss \[[@B23-ijms-17-01800]\]. Microalbuminuria is widely used as a surrogate endpoint to assess renal function in patients with diabetic nephropathy \[[@B24-ijms-17-01800],[@B25-ijms-17-01800],[@B26-ijms-17-01800]\]. The Cr and urea nitrogen of all patients at baseline are 0.72 ± 0.33 mg/dL and 13.06 ± 0.77 mg/dL, respectively, and these are normal values. Almost all of the patients in this study are in the stage of microalbuminuria. Therefore, the 24-week observation period of this study is too short to check the improvements of serum Cr, Cr clearance and eGFR. The present data demonstrated that an ARB, olmesartan, could decrease urinary excretions of albumin ([Figure 3](#ijms-17-01800-f003){ref-type="fig"}), as well as AGT ([Figure 4](#ijms-17-01800-f004){ref-type="fig"}), suggesting that an ARB has albuminuria reduction effects in patients with metabolic syndrome. Moreover, ΔUAlbCR ([Figure 6](#ijms-17-01800-f006){ref-type="fig"}a), as well as the % change in UAlbCR ([Figure 6](#ijms-17-01800-f006){ref-type="fig"}b) were significantly lower in Group H, who had a higher value of UAGTCR before the ARB treatment than in Group L, who had a lower value of UAGTCR before the ARB treatment, even though clinical characteristics ([Table 4](#ijms-17-01800-t004){ref-type="table"}) and baseline laboratory data ([Table 5](#ijms-17-01800-t005){ref-type="table"}) partitioned by the cutoff value of UAGTCR before the ARB treatments were equivalent between the two groups. These data suggest that urinary AGT excretion could be a prognostic marker of the albuminuria reduction effects of ARB in patients with metabolic syndrome.

There was no correlation between UAGTCR or UAlbCR and blood pressure (correlation with UAGTCR and systolic blood pressure (SBP): *R*^2^ = 0.000609, *r* = −0.0247, *p* = 0.909; correlation with UAGTCR and DBP: *R*^2^ = 0.00635, *r* = −0.0797, *p* = 0.711; correlation with UAlbCR and SBP: *R*^2^ = 0.0178, *r* = 0.133, *p* = 0.534; correlation with UAlbCR and diastolic blood pressure (DBP): *R*^2^ = 0.0114, *r* = 0.107, *p* = 0.620). These data suggest that in patients with metabolic syndrome, the albuminuria reduction effects of ARB are independent of the anti-hypertensive actions of ARB, but exert themselves via other mechanisms. Their mechanisms are the RAS/angiotensin II type I receptor pathway beyond the anti-hypertensive actions of ARB, which do not pass through the blood pressure-lowering effect of ARB. One of the possible mechanisms of CKD in metabolic syndrome patients is the activation of the RAS. Several mechanisms of the activation of the RAS are sympathetic stimulation \[[@B27-ijms-17-01800]\], synthesis of adipocytokines in the RAS by visceral fat tissues \[[@B28-ijms-17-01800]\] and renal hemodynamic alterations \[[@B29-ijms-17-01800]\] despite sodium retention and clearly increased extracellular fluid volume in patients with metabolic syndrome \[[@B30-ijms-17-01800],[@B31-ijms-17-01800]\]. The local/tissue RAS in specific tissues is associated with organ injury in the brain, heart, adrenal glands, vasculature and kidneys \[[@B15-ijms-17-01800]\]. Kidneys have AGT \[[@B32-ijms-17-01800]\], renin \[[@B33-ijms-17-01800],[@B34-ijms-17-01800]\] and angiotensin-converting enzyme (ACE) \[[@B35-ijms-17-01800]\] in their proximal and distal tubular cells. Thus, angiotensin II could be locally generated in the kidney \[[@B15-ijms-17-01800]\]. Once angiotensin II concentration increases in the kidneys, AGT, which is the sole substrate of the RAS, will be increased further \[[@B32-ijms-17-01800]\]. In rat glomerular cells, angiotensin II causes increasing tumor cell growth factor β1 and renal damage by hypertrophy and fibrosis \[[@B36-ijms-17-01800],[@B37-ijms-17-01800]\]. The RAS in the kidneys is involved in the development and progression of renal injury \[[@B7-ijms-17-01800],[@B21-ijms-17-01800],[@B22-ijms-17-01800]\]. The intrarenal RAS is activated in obesity \[[@B12-ijms-17-01800],[@B13-ijms-17-01800]\]. This study suggests that in metabolic syndrome patients with activated intrarenal RAS, ARB has albuminuria reduction effects. Activation of the intrarenal RAS is the primary cause of renal injury in patients with metabolic syndrome \[[@B3-ijms-17-01800]\].

There may be a correlation between UAGTCR and Cr clearance. AGT mRNA in the kidneys has been localized on the proximal tubule cells. This locally-formed and secreted AGT could dictate the intratubular angiotensin II \[[@B38-ijms-17-01800],[@B39-ijms-17-01800]\]. It was reported that UAGTCR was correlated with mRNA and protein levels of AGT in renal tissues with IgA nephropathy \[[@B21-ijms-17-01800],[@B31-ijms-17-01800]\]. Treatment with ARB decreased mRNA and protein levels of AGT in renal tissues and urinary AGT levels \[[@B21-ijms-17-01800],[@B40-ijms-17-01800]\]. Urinary AGT may be unaffected by renal plasma flow or glomerular filtration rate \[[@B21-ijms-17-01800]\]. These data suggest that the intrarenal RAS is independent of the circulating RAS and that ARB suppresses the activation of the intrarenal RAS. We previously reported that the olmesartan treatment decreased intrarenal AGT mRNA/protein levels, as well as urinary AGT levels in angiotensin II-infused rats \[[@B41-ijms-17-01800]\]. We believe that this mechanism may account for the low levels of urinary AGT by olmesartan treatment in this study.

There were several possible explanations for how the activation of RAS in the proximal tubule cells could lead to glomerular injuries, such as albuminuria. The following three interpretations may explain this issue. First, the increase of AGT in proximal tubular cells may lead to the increase in angiotensin II in renal tissues \[[@B21-ijms-17-01800]\], which may cause a rise of the intra-glomerular pressure and lead to glomerular injuries \[[@B7-ijms-17-01800],[@B42-ijms-17-01800]\].

Secondly, the AGT produced in proximal tubular cells appears to be secreted directly into the apical side of the tubular lumen \[[@B43-ijms-17-01800]\]. In addition, the AGT produced in proximal tubular cells may be secreted into the basolateral side of the tubular lumen \[[@B38-ijms-17-01800]\]. In a study using the polar proximal tubule cell culture system, AGT was secreted into the basolateral side of the tubular lumen \[[@B44-ijms-17-01800]\]. The secreted AGT in the interstitium may cause changes in the interstitial circumstances and, consequently, cause glomerular injury \[[@B45-ijms-17-01800]\].

Finally, AGT was mainly expressed in proximal tubular cells in the kidney \[[@B38-ijms-17-01800]\]. However, AGT was also expressed in glomerular cells, particularly in the mesangial cells under pathological conditions, such as diabetes \[[@B46-ijms-17-01800],[@B47-ijms-17-01800],[@B48-ijms-17-01800],[@B49-ijms-17-01800]\]. It has been demonstrated that intrarenal AGT levels increase in diabetic rats \[[@B48-ijms-17-01800],[@B49-ijms-17-01800]\] and humans \[[@B50-ijms-17-01800]\] before generating renal damage. The increase in intrarenal AGT formation underlying type 2 diabetes \[[@B51-ijms-17-01800],[@B52-ijms-17-01800]\] may be associated with the onset of diabetic nephropathy \[[@B15-ijms-17-01800],[@B46-ijms-17-01800],[@B53-ijms-17-01800]\].

4. Materials and Methods {#sec4-ijms-17-01800}
========================

4.1. Participants and Protocols {#sec4dot1-ijms-17-01800}
-------------------------------

This experimental protocol was approved on 29 November 2007 by the Institutional Review Board of Kagawa University School of Medicine (Kagawa, Japan, IRB: \#2007CS015) and registered (UMIN 000001030). Participants with metabolic syndrome were recruited from Kagawa University, Toyama University, or Kansai Medical University from February 2008--June 2011, and written informed consent forms were obtained. Participants were patients with metabolic syndrome who met the following conditions: patients were between 20 and 70 years old, untreated by ARBs, ACE inhibitors or diuretics for the preceding 4 weeks, body mass index (BMI) ≥ 25 or (waist ≥ 85 cm (Men) or ≥ 90 cm (Women)), clinic SBP ≥ 130 mmHg or DBP ≥ 85 mmHg. In addition, at least one criterion from the following conditions was required: TG ≥ 150 mg/dL, high-density lipoprotein-cholesterol (HDLc) ≤ 40 mg/dL and/or FBS ≥ 110 mg/dL. Exclusion criteria for patients included pregnancy, treatment with ARBs, ACE inhibitors or diuretics within 4 weeks, patients with diabetes mellitus who were treated with anti-diabetic drugs, severe hypertension (SBP ≥ 160 mmHg or DBP ≥ 110 mmHg), secondary hypertension, severe renal disease (UAlbCR \> 300 mg/g Cr, Cr clearance \< 30 mL/min, serum Cr ≥ 2.0 mg/dL), severe hepatic disease (AST ≥ 150 IU/L or ALT ≥150 IU/L), history of major cardiac or cerebrovascular events, endocrine diseases and patients with malignancies.

4.2. Protocol {#sec4dot2-ijms-17-01800}
-------------

The participants took olmesartan 5--40 mg/day for 24 weeks. Blood pressure was checked every 4 weeks, and the amount of olmesartan was adjusted based on blood pressure (less than 130/85 mmHg and more than 100/50 mmHg). If blood pressure in patients who took 40 mg/day olmesartan over 8 weeks reached more than 150/100 mmHg, they were excluded. Blood and urine samples were collected at baseline (0 weeks) and at 12 and 24 weeks after treatment. Blood pressure was measured at baseline (0 weeks) and 4, 8, 12, 16, 20 and 24 weeks after treatment in clinic.

4.3. Measurements {#sec4dot3-ijms-17-01800}
-----------------

AGT, renin activity at rest, aldosterone, FBS and TG were measured in the 0-, 12- and 24-week blood samples. Albumin, AGT and Cr were measured in the 0-, 12- and 24-week urine samples. Blood pressure and body weight were measured in the 0-, 4-, 8-, 12-, 16-, 20- and 24-week samples. Plasma and urinary AGT concentrations were measured by the human AGT ELISA kit (IBL, Gunma, Japan) \[[@B54-ijms-17-01800]\].

4.4. Statistical Analysis {#sec4dot4-ijms-17-01800}
-------------------------

All statistical analyses were performed with JMP software Version 10 (SAS Institute, Inc., Tokyo, Japan) and GraphPad Prism software Version 6 (GraphPad Software, Inc., La Jolla, CA, USA). Clinical characteristics and laboratory data of all patients at baseline are reported as the mean ± S.E.M. One-way repeated measures ANOVA followed by Tukey's multiple comparisons test were used to compare values over the time course. Logistic analysis was conducted based on whether or not UAlbCR decreased less than −50% by olmesartan treatment. The ROC curve was developed; the AUC was calculated; and the optimal cutoff value was determined. Based on this cutoff value of UAGTCR before the treatment, patients were subdivided into 2 groups. Then, the % changes in UAlbCR and ΔUAlbCR were compared between the 2 groups using the unpaired *t*-test. *p* \< 0.05 was considered as statistically significant.

5. Conclusions {#sec5-ijms-17-01800}
==============

Our data demonstrate that olmesartan, an ARB, could decrease urinary excretions of albumin, as well as AGT in patients with metabolic syndrome. In addition, we show that urinary AGT excretion could be a prognostic marker of the albuminuria reduction effects of ARB in patients with metabolic syndrome. Based on the findings in this study, treatment with ARB might be recommended in untreated patients with metabolic syndrome who showed a higher value of urinary AGT before treatment.

We used only one ARB, olmesartan, but did not use multiple ARBs in this study. If we used multiple ARBs in the first study, we would not be able to judge a specific action of a specific ARB or a class-effect of ARBs. We realize that the sample size is relatively small, and there is not a control group. These are limitations of this study. Unfortunately, however, the patient recruitment in this registered clinical trial was ended, and it is not possible to increase the sample size in this study. In order to address these issues, we are now planning larger scale prospective clinical studies using multiple ARBs.

The authors would like to acknowledge Loula Burton (Tulane University Health Sciences Center) for her constructive suggestions in order to polish the manuscript. The authors also thank Yoshiko Fujita (Kagawa University School of Medicine) for her excellent technical assistance.

Supplementary materials can be found at [www.mdpi.com/1422-0067/17/11/1800/s1](www.mdpi.com/1422-0067/17/11/1800/s1).
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![Systolic and diastolic blood pressure was decreased after the treatment with olmesartan. One-way repeated measures ANOVA followed by Tukey's multiple comparisons test were used to compare values over the time course. *p* \< 0.05 was considered as statistically significant (\* *p* \< 0.05).](ijms-17-01800-g001){#ijms-17-01800-f001}

![(**a**) Plasma renin activity was increased after the treatment with olmesartan; (**b**) treatment with olmesartan did not affect plasma aldosterone concentrations. One-way repeated measures ANOVA followed by Tukey's multiple comparisons test were used to compare values over the time course. *p* \< 0.05 was considered as statistically significant (\* *p* \< 0.05).](ijms-17-01800-g002){#ijms-17-01800-f002}

![The urinary albumin/creatinine ratio was decreased after the treatment with olmesartan. One-way repeated measures ANOVA followed by Tukey's multiple comparisons test were used to compare values over the time course. *p* \< 0.05 was considered as statistically significant (\* *p* \< 0.05). UAlbCR, average urinary albumin/creatinine.](ijms-17-01800-g003){#ijms-17-01800-f003}

![The urinary angiotensinogen/creatinine ratio was decreased after the treatment with olmesartan. One-way repeated measures ANOVA followed by Tukey's multiple comparisons test were used to compare values over the time course. *p* \< 0.05 was considered as statistically significant (\* *p* \< 0.05). UAGTCR, average urinary angiotensinogen (AGT)/creatinine.](ijms-17-01800-g004){#ijms-17-01800-f004}

###### 

(**a**) Patients were divided into two groups based on whether or not the urinary albumin/creatinine ratio decreased less than 50%. The good responder group was defined as % change in urinary albumin/creatinine ratio \<−50%; (**b**) Logistic analysis was conducted by the urinary angiotensinogen/creatinine ratio before the treatments. The receiver operating characteristic (ROC) curve was plotted. The vertical axis shows whether the urinary albumin/creatinine ratio decreased less than 50%; (**c**) Area under the curve (AUC): 0.694; cutoff value of urinary angiotensinogen/creatinine ratio: 13.9 µg/g Cr; maximum Youden index: 0.500 ((**b**,**c**) specificity: 11/12 = 91.7% and sensitivity: 07/12 = 58.3%).

![](ijms-17-01800-g005a)

![](ijms-17-01800-g005b)

![ΔUrinary albumin/creatinine ratio and % change in the urinary albumin/creatinine ratio portioned by the cutoff value of the urinary angiotensinogen/creatinine ratio before treatments. They were compared between thetwo2 groups using the unpaired *t*-test. *p* \< 0.05 was considered as statistically significant. (**a**) The ΔUrinary albumin/creatinine ratio was significantly lower in Group H than in Group L; (**b**) in addition, the % change in the urinary albumin/creatinine ratio was significantly lower in Group H than in Group L (\* *p* \< 0.05).](ijms-17-01800-g006){#ijms-17-01800-f006}

ijms-17-01800-t001_Table 1

###### 

Clinical characteristics of all patients at baseline.

  Parameters               Means ± SEM
  ------------------------ -------------
  Sex (Women/Men)          (8/16)
  Age                      57.9 ± 2.0
  Height (cm)              165 ± 2
  Weight (kg)              73.1 ± 2.4
  BMI                      26.9 ± 0.8
  Waist (cm)               91.0 ± 2.0
  Smoke (Yes/No)           (4/20)
  Drink (Yes/No)           (13/11)
  Exercises (Yes/No)       (2/22)
  SBP (mmHg)               158 ± 2
  DBP (mmHg)               95 ± 3
  Heart Rate (beats/min)   72.7 ± 2.2

BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; SEM: standard error of the mean.

ijms-17-01800-t002_Table 2

###### 

Laboratory data of all patients at baseline.

  Parameters                Means ± SEM
  ------------------------- -------------
  FBS (mg/dL)               107 ± 4
  Insulin (µU)              5.75 ± 0.81
  HbA1c (%)                 5.48 ± 0.08
  TG (mg/dL)                117 ± 13
  TC (mg/dL)                186 ± 6
  LDLc (mg/dL)              107 ± 5
  HDLc (mg/dL)              56.0 ± 3.0
  AST (IU/L)                25.6 ± 2.5
  ALT (IU/L)                26.5 ± 4.0
  γGTP (IU/L)               61.9 ± 17.8
  BUN (mg/dL)               13.1 ± 0.8
  Cr (mg/dL)                0.72 ± 0.03
  Uric Acid (mg/dL)         5.86 ± 0.25
  PRA (ng/mL/h)             0.98 ± 0.22
  Aldosterone (pg/mL)       60.8 ± 9.9
  Na (mEq/L)                141 ± 0
  K (mEq/L)                 3.93 ± 0.05
  Cl (mEq/L)                105 ± 0
  White Blood Cells (/µL)   5060 ± 253
  Hemoglobin (g/dL)         13.3 ± 0.3
  Platelets (×10^4^/µL)     21.1 ± 1.0

FBS: fasting blood sugar; TG: triglyceride; TC: total cholesterol; LDL: low-density lipoprotein-cholesterol; HDL: high-density lipoprotein-cholesterol; AST: aspartate transaminase; ALT: alanine transaminase; γ-GTP: γ-glutamyl trans peptidase; BUN: urea nitrogen; Cr: creatinine; PRA: plasma renin activity.

ijms-17-01800-t003_Table 3

###### 

Clinical characteristics of the poor responder group and the good responder group at the baseline.

  Parameters                  Poor Responder Group   Good Responder Group   χ^2^    *p*-Values
  --------------------------- ---------------------- ---------------------- ------- ------------
  Sex (Women/Men)             (4/8)                  (4/8)                  0.000   1.000
  Age                         55.5 ± 2.4             60.3 ± 3.2                     0.244
  Height (cm)                 167 ± 3                163 ± 2                        0.163
  Weight (kg)                 73.5 ± 3.7             72.8 ± 3.3                     0.883
  BMI                         26.3 ± 1.3             27.5 ± 0.9                     0.447
  Waist (cm)                  90.1 ± 3.0             91.9 ± 2.6                     0.651
  Smoke (Yes/No)              (3/9)                  (1/11)                 1.200   0.273
  Drink (Yes/No)              (7/5)                  (6/6)                  0.168   0.682
  Exercises (Yes/No)          (1/11)                 (1/11)                 0.000   1.000
  SBP (mmHg)                  154 ± 2                162 ± 4                        0.084
  DBP (mmHg)                  94 ± 3                 95 ± 5                         0.818
  Heart Rate (beats/minute)   72.0 ± 2.9             73.3 ± 3.4                     0.766
  UAlbCR (mg/g Cr)            139 ± 64               69 ± 38                        0.356

BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; UAlbCR: urinary albumin/creatinine ratio.

ijms-17-01800-t004_Table 4

###### 

Clinical characteristics of the low urinary angiotensinogen (AGT) group and the high urinary AGT group at the baseline.

  Parameters               Low Group    High Group   χ^2^    *p*-Values
  ------------------------ ------------ ------------ ------- ------------
  Sex (Women/Men)          (3/5)        (5/11)       0.094   0.760
  Age                      58.5 ± 3.0   57.6 ± 2.7           0.818
  Height (cm)              164 ± 3      165 ± 2              0.821
  Weight (kg)              73.5 ± 2.4   73.0 ± 3.4           0.903
  BMI                      27.3 ± 1.1   26.7 ± 1.1           0.696
  Waist (cm)               91.6 ± 3.0   90.7 ± 2.6           0.813
  Smoke (Yes/No)           (2/6)        (2/14)       0.600   0.439
  Drink (Yes/No)           (5/3)        (8/8)        0.336   0.562
  Exercises (Yes/No)       (1/7)        (1/15)       0.273   0.602
  SBP (mmHg)               154 ± 4      160 ± 3              0.208
  DBP (mmHg)               91 ± 4       96 ± 4               0.342
  Heart Rate (beats/min)   72.0 ± 4.9   73.0 ± 2.3           0.857
  UAlbCR (mg/g Cr)         8 ± 2        153 ± 52             0.0136 \*

BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; UAlbCR: urinary albumin/creatinine ratio; \* *p* \< 0.05.

ijms-17-01800-t005_Table 5

###### 

Laboratory data for the low urinary AGT group and the high urinary AGT group at the baseline.

  Parameters                Low Group     High Group    *p*-Values
  ------------------------- ------------- ------------- ------------
  FBS (mg/dL)               110 ± 3       105 ± 6       0.476
  Insulin (µU)              5.18 ± 1.00   6.01 ± 1.11   0.588
  HbA1c (%)                 5.39 ± 0.13   5.53 ± 0.10   0.408
  TG (mg/dL)                115 ± 20      118 ± 16      0.912
  TC (mg/dL)                188 ± 10      184 ± 7       0.758
  LDLc (mg/dL)              113 ± 6       103 ± 8       0.359
  HDLc (mg/dL)              53.1 ± 5.8    57.4 ± 3.5    0.541
  AST (IU/L)                21.3 ± 2.1    27.8 ± 3.6    0.131
  ALT (IU/L)                20.9 ± 2.3    29.4 ± 5.8    0.188
  γGTP (IU/L)               31.6 ± 5.8    77.0 ± 26.1   0.108
  BUN (mg/dL)               13.5 ± 1.3    12.8 ± 1.0    0.679
  Cr (mg/dL)                0.68 ± 0.05   0.74 ± 0.03   0.315
  Uric Acid (mg/dL)         5.48 ± 0.47   6.05 ± 0.30   0.320
  PRA (ng/mL/hr)            1.14 ± 0.45   0.91 ± 0.26   0.659
  Aldosterone (pg/mL)       50.8 ± 21.1   65.2 ± 11.2   0.562
  Na (mEq/L)                141 ± 0       142 ± 0       0.196
  K (mEq/L)                 3.98 ± 0.08   3.90 ± 0.06   0.467
  Cl (mEq/L)                104 ± 1       105 ± 0       0.554
  White Blood Cells (/µL)   4720 ± 268    5220 ± 354    0.267
  Hemoglobin (g/dL)         13.5 ± 0.4    13.2 ± 0.5    0.603
  Platelets (×10^4^/µL)     22.3 ± 1.6    20.5 ± 1.4    0.402

FBS: fasting blood sugar; TG: triglyceride; TC: total cholesterol; LDL: low-density lipoprotein-cholesterol; HDL: high-density lipoprotein-cholesterol; AST: aspartate transaminase; ALT: alanine transaminase; γ-GTP: γ-glutamyl trans peptidase; BUN: urea nitrogen; Cr: creatinine; PRA: plasma renin activity.
